Overview
Jaundice of the newborn, also called **neonatal jaundice**, is a common condition in which a baby’s skin and the whites of the eyes develop a yellow tint. The discoloration is caused by a buildup of bilirubin – a yellow pigment produced when red blood cells break down. In most cases the condition is harmless and resolves on its own, but very high bilirubin levels can lead to brain injury (kernicterus) if not treated promptly.
- Who it affects: Almost all newborns develop at least mild jaundice. The condition is most frequent in full‑term infants (≈ 60 % within the first week) and even more common in pre‑term infants (≈ 80 %).
- Prevalence: According to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), clinically significant jaundice (bilirubin ≥ 15 mg/dL) occurs in about 5–10 % of term infants and up to 25 % of pre‑term infants.
- Age of onset: Jaundice typically appears after the first 24 hours** of life. If it is present within the first 24 h, the risk of serious disease is higher and warrants immediate evaluation.
Symptoms
Newborn jaundice usually begins on the face and spreads downward. The degree of yellowing often correlates with the bilirubin level.
Typical Signs
- Yellow skin: Starts on the face, chin, and neck, then moves to the chest, abdomen, arms, and legs. In severe cases the palms and soles turn yellow.
- Yellow sclera (whites of the eyes): Usually appears after the skin becomes yellow.
- Feeding difficulties: Babies may be sluggish, less interested in feeding, or have a weak suck.
- Excessive sleepiness: While newborns sleep a lot, unusually deep or prolonged sleep can be a warning sign.
- High‑pitched cry: A cry that sounds “tight” or “piercing” may indicate rising bilirubin.
Less Common or Late‑Onset Symptoms
- Dark urine (bilirubin excreted in urine)
- Pale or clay‑colored stools (bilirubin not reaching the intestines)
- Fever, vomiting, or poor weight gain (suggesting another underlying problem)
Causes and Risk Factors
Jaundice results from an imbalance between bilirubin production and the newborn’s ability to eliminate it. Several factors increase this risk.
Physiologic (normal) causes
- Immature liver enzyme systems: Newborns, especially pre‑term, lack fully functional UDP‑glucuronosyltransferase (UGT1A1) needed to conjugate bilirubin.
- Higher red‑blood‑cell turnover: Fetal hemoglobin is broken down more rapidly after birth.
Pathologic causes
- Hemolytic disease of the newborn (HDN): Incompatible blood types (e.g., ABO or Rh incompatibility) cause rapid red‑cell destruction.
- Breast‑milk jaundice: Certain substances in breast milk (e.g., β‑glucuronidase) can interfere with bilirubin processing; typically appears after 3–5 days.
- Breast‑feeding failure jaundice: Inadequate intake during the first days leads to dehydration and reduced bilirubin elimination.
- Genetic enzyme deficiencies: Crigler‑Najjar syndrome, Gilbert syndrome.
- Infection: Sepsis or urinary tract infection can impair liver function.
- Blood group incompatibility (e.g., G6PD deficiency): Leads to hemolysis.
Key risk factors
- Prematurity or low birth weight (< 2500 g)
- Breast‑feeding difficulties or delayed initiation of feeding
- Maternal diabetes, hypertension, or use of certain medications (e.g., sulfonamides)
- Sibling with a history of severe jaundice
- East Asian or Mediterranean ancestry (higher prevalence of G6PD deficiency)
- Bruising or birth trauma causing internal bleeding
Diagnosis
Early recognition and accurate measurement of bilirubin are essential. Diagnosis combines visual assessment with quantitative testing.
1. Clinical Examination
- Physical exam of skin and sclera.
- Assessment of feeding patterns, hydration status, and activity level.
2. Transcutaneous Bilirubin (TcB) Screening
A painless device placed on the infant’s forehead or sternum provides an estimate of bilirubin. It is useful for screening but must be confirmed with serum testing if levels are high or the baby is < 24 h old.
3. Serum Total Bilirubin (TB) Test
- Blood sample (usually from a heel stick) measured in mg/dL.
- Results are plotted on an age‑specific phototherapy nomogram (e.g., the American Academy of Pediatrics [AAP] chart) to determine treatment thresholds.
4. Additional Laboratory Tests (when indicated)
- Complete blood count (CBC) – to look for anemia or infection.
- Peripheral blood smear – to evaluate for hemolysis.
- Blood type and Coombs test – for immune‑mediated hemolysis.
- Liver function panel – if hepatic disease is suspected.
Treatment Options
Therapy aims to keep bilirubin below the level at which it can cross the blood‑brain barrier. The choice depends on the bilirubin concentration, infant’s age, and presence of risk factors.
1. Phototherapy (Light Therapy)
- How it works: Blue‑green light (≈460 nm) converts bilirubin in the skin into water‑soluble isomers that can be excreted without liver metabolism.
- Types: Conventional (overhead lamps), fiber‑optic blankets, or LED devices. LED units are now standard due to higher efficacy and less heat.
- Typical duration: 12–24 h until bilirubin falls below treatment threshold, then weaning.
2. Exchange Transfusion
- Reserved for bilirubin levels > 20–25 mg/dL (or lower if risk factors exist) or when phototherapy fails.
- Procedure replaces the infant’s blood with donor blood, rapidly removing bilirubin and antibodies.
- Requires a pediatric intensive‑care setting and carries risks (electrolyte imbalance, infection).
3. Intravenous Immunoglobulin (IVIG)
- Used in immune‑mediated hemolysis (e.g., Rh incompatibility) to reduce antibody‑mediated red‑cell destruction.
- Often combined with phototherapy to avoid exchange transfusion.
4. Optimizing Feeding
- Frequent breastfeeding (every 2–3 h) or formula supplementation reduces enterohepatic circulation of bilirubin.
- Breast‑feeding support from lactation consultants is crucial, especially for “breast‑feeding failure jaundice.”
5. Medications
- There are no drugs that directly lower bilirubin safely in newborns; the focus remains on phototherapy and supportive care.
Living with Jaundice of the Newborn
While treatment is underway, families can take practical steps to support recovery and reduce stress.
- Maintain regular feeds: Aim for 8–12 feedings per day. Monitor urine output (≥ 1 mL/kg/h) and stool frequency (≥ 3 yellow stools daily).
- Skin care: Keep the baby’s skin clean and dry; avoid lotions that could interfere with light penetration during phototherapy.
- Monitor temperature: Babies under phototherapy can become dehydrated or over‑cooled. Check skin temperature every few hours.
- Track bilirubin levels: Keep a log of each lab result and the corresponding treatment plan.
- Family involvement: Parents can stay with the infant during phototherapy (unless a blanket device is used) to provide comfort and promote bonding.
- Discharge readiness: Before leaving the hospital, ensure the pediatrician has a follow‑up plan, usually a bilirubin recheck within 24–48 h.
Prevention
Many cases of neonatal jaundice are unavoidable, but several measures can lower the likelihood of severe disease.
- Early and adequate feeding: Initiate breastfeeding within the first hour of life when possible; aim for at least 30 mL/kg/day by day 3.
- Maternal health optimization: Control gestational diabetes and hypertension; screen for blood‑type incompatibilities.
- Vitamin K prophylaxis: Reduces bleeding that could increase bilirubin production.
- Screening for G6PD deficiency: Particularly in high‑risk ethnic groups; early identification allows closer monitoring.
- Educate families: Explain normal jaundice timing and warning signs before discharge.
Complications
If bilirubin becomes excessively high (≥ 20 mg/dL) or rises rapidly, it can cross the blood‑brain barrier and cause irreversible damage.
- Kernicterus (bilirubin‑induced neurological dysfunction): Presents with lethargy, poor feeding, high‑pitch cry, hypotonia, and later, movement disorders, auditory deficits, and cerebral palsy.
- Acute bilirubin encephalopathy: Early reversible stage of kernicterus; may improve with rapid bilirubin reduction.
- Chronic hemolysis or anemia: Particularly in hemolytic disease.
- Hearing loss: Reported in up to 20 % of infants with severe untreated jaundice.
- Neurodevelopmental delays: Long‑term follow‑up may be needed for children who experienced high bilirubin levels.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if your newborn shows any of the following:
- Yellowing of the skin or eyes that appears within the first 24 hours of life.
- Very rapid spread of jaundice (e.g., from face to torso in < 6 hours).
- Bilirubin level reported by a clinician as > 20 mg/dL (or > 15 mg/dL in a pre‑term infant).
- Extreme sleepiness, difficulty waking for feeds, or a high‑pitched, weak cry.
- Feeding less than half of usual amount, poor weight gain, or fewer than 3 wet diapers in 24 h.
- Signs of dehydration: dry mouth, sunken fontanelle, or tearless crying.
- Any seizure‑like activity, stiffening, or abnormal movements.
These signs may indicate bilirubin‑induced brain injury and require prompt intervention.
References
- American Academy of Pediatrics. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022.
- Mayo Clinic. “Newborn Jaundice.” Accessed March 2024.
- National Institute of Child Health and Human Development (NICHD). “Neonatal Jaundice.” 2023.
- World Health Organization. “Neonatal Jaundice: Guidelines for Diagnosis and Treatment.” 2021.
- Cleveland Clinic. “Neonatal Jaundice.” Updated 2024.
- Centers for Disease Control and Prevention. “Hyperbilirubinemia and Kernicterus.” 2023.